News & Updates

Show Multimedia Only

From nontargeted therapy to CGRP-targeted therapy: Breakthrough in first-line migraine prevention

30 Dec 2025 by

Migraine is a highly disabling neurological condition that profoundly affects patients’ quality of life (QoL) and productivity. Traditional first-line (1L) preventive treatments were not originally developed for migraine and are often limited by suboptimal efficacy and poor tolerability. In an interview with MIMS Doctor, Dr William Kingston of the Division of Neurology, Department of Medicine, Temerty School of Medicine, University of Toronto, Canada, discussed the emergence of calcitonin gene–related peptide (CGRP) inhibitors, including atogepant, as a significant breakthrough in migraine prevention, offering targeted, migraine[1]specific efficacy with improved tolerability.

From nontargeted therapy to CGRP-targeted therapy: Breakthrough in first-line migraine prevention

30 Dec 2025

Clinically meaningful benefits and biological clearance of amyloid load after initiating and continuing lecanemab treatment in two patients with Alzheimer’s disease

21 Nov 2025 by

Two Hong Kong patients achieved clinical stabilization along with amyloid burden reduction after ≥12 months of lecanemab treatment.

Clinically meaningful benefits and biological clearance of amyloid load after initiating and continuing lecanemab treatment in two patients with Alzheimer’s disease

21 Nov 2025

Oral gepants: Revolutionizing migraine management in primary care

15 Nov 2025 by

Migraine is a common and debilitating neurological disorder that significantly impacts daily functioning and quality of life (QoL). Despite its high prevalence, migraine remains underdiagnosed and undertreated, particularly in the primary care setting. In an interview with MIMS Doctor, Professor Lawrence Wong, Emeritus Professor of the Department of Medicine and Therapeutics, Chinese University of Hong Kong, highlighted the importance of early diagnosis and timely intervention in migraine management. He noted that calcitonin gene-related peptide (CGRP)–targeted therapies, specifically oral gepants, offer a convenient and effective option for primary care providers (PCPs) to prevent migraine attacks and reduce the long-term burden of the condition.

Oral gepants: Revolutionizing migraine management in primary care

15 Nov 2025

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

15 Aug 2025

At the recent COVID-CONNECT Masterclass, an expert-led session explored where COVID-19 stands among common viral infections today. In a non-promotional symposium supported by Pfizer, infectious disease specialist Dr Leong Hoe Nam, Mount Elizabeth Hospital Novena, Singapore, discussed strategies for managing viral infections and surge preparedness. Complementing this, Professor David Strain from the University of Exeter Medical School, UK highlighted the enduring burden of long COVID.

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

15 Aug 2025

RW study in Chinese migraine patients: Rimegepant effective with high satisfaction rates

18 Jul 2025

Rimegepant as an acute treatment for migraine is effective with high patient satisfaction rates, a real-world (RW) registry study in Chinese patients has shown.

RW study in Chinese migraine patients: Rimegepant effective with high satisfaction rates

18 Jul 2025

Pre-symptomatic diagnosis and treatment: A game changer for SMA

28 Feb 2025 by

Spinal muscular atrophy (SMA) is a progressive neurodegenerative disease that typically begins to manifest in infancy or childhood. Early diagnosis and prompt treatment before symptom onset can significantly improve clinical outcomes, including survival and attainment of motor milestones. At an industry-sponsored symposium co-organized by the Hong Kong Society of Neuromuscular Diseases (HKSNMD), Dr Astrid Blaschek of Dr von Hauner Children's Hospital in Munich, Germany, discussed implementation of the genetic newborn screening (NBS) programme for SMA in Germany and her clinical experience in managing children with SMA with available disease-modifying therapies, including risdiplam.

Pre-symptomatic diagnosis and treatment: A game changer for SMA

28 Feb 2025

Migraine: Rimegepant as dual treatment heralds a new paradigm

09 Feb 2025

Rimegepant, an oral calcitonin gene–related peptide (CGRP)–targeted therapy indicated for both acute and preventive treatment of migraine, heralds a new paradigm in long-term management of the condition.

Migraine: Rimegepant as dual treatment heralds a new paradigm

09 Feb 2025

CTAD 2024: Origin of lecanemab and real-world experience in its use

20 Jan 2025 by

At the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference held in Madrid, Spain, researchers from the US and Japan shared real-world clinical experience with lecanemab, the first approved disease-modifying treatment for early Alzheimer’s disease (AD). Professor Lars Lannfelt of Uppsala University, Sweden, who received the CTAD Lifetime Achievement Award in recognition of his pioneering work that led to the development of the monoclonal antibody (mAb) drug, described the origins of his ground-breaking discovery.

CTAD 2024: Origin of lecanemab and real-world experience in its use

20 Jan 2025

TTFields use in special GBM populations and potential combination with immunotherapy

14 Feb 2023 by

Glioblastoma multiforme (GBM) is the most common and aggressive brain tumour with a very poor prognosis. Tumour-treating fields (TTFields) are a relatively new, noninvasive treatment for GBM, which delivers low-intensity alternating electric fields that disrupt cancer cell division. At a recent scientific meeting organized by the Hong Kong Neurosurgical Society, Dr Alexander Grote of the Department of Neurosurgery, University Hospital of Marburg, Germany, and Professor Michael Lim of the Department of Neurosurgery, Stanford University, US, discussed the evolving role of TTFields in managing patients with GBM.

TTFields use in special GBM populations and potential combination with immunotherapy

14 Feb 2023

News & Updates

Filter by Specialty:

Specialty:

From nontargeted therapy to CGRP-targeted therapy: Breakthrough in first-line migraine prevention

From nontargeted therapy to CGRP-targeted therapy: Breakthrough in first-line migraine prevention

Clinically meaningful benefits and biological clearance of amyloid load after initiating and continuing lecanemab treatment in two patients with Alzheimer’s disease

Clinically meaningful benefits and biological clearance of amyloid load after initiating and continuing lecanemab treatment in two patients with Alzheimer’s disease

Oral gepants: Revolutionizing migraine management in primary care

Oral gepants: Revolutionizing migraine management in primary care

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

RW study in Chinese migraine patients: Rimegepant effective with high satisfaction rates

RW study in Chinese migraine patients: Rimegepant effective with high satisfaction rates

Pre-symptomatic diagnosis and treatment: A game changer for SMA

Pre-symptomatic diagnosis and treatment: A game changer for SMA

Migraine: Rimegepant as dual treatment heralds a new paradigm

Migraine: Rimegepant as dual treatment heralds a new paradigm

CTAD 2024: Origin of lecanemab and real-world experience in its use

CTAD 2024: Origin of lecanemab and real-world experience in its use

TTFields use in special GBM populations and potential combination with immunotherapy

TTFields use in special GBM populations and potential combination with immunotherapy